Positron emission tomography-based response to target and immunotherapies in oncology

Maria Isabella Donegani, Giulia Ferrarazzo, Stefano Marra, Alberto Miceli, Stefano Raffa, Matteo Bauckneht, Silvia Morbelli

Research output: Contribution to journalReview articlepeer-review


2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is a promising tool to support the evaluation of response to either target therapies or immunotherapy with immune checkpoint inhibitors both in clinical trials and, in selected patients, at the single patient’s level. The present review aims to discuss available evidence related to the use of [18F]FDG PET (Positron Emission Tomography) to evaluate the response to target therapies and immune checkpoint inhibitors. Criteria proposed for the standardization of the definition of the PET-based response and complementary value with respect to morphological imaging are commented on. The use of PET-based assessment of the response through metabolic pathways other than glucose metabolism is also relevant in the framework of personalized cancer treatment. A brief discussion of the preliminary evidence for the use of non-FDG PET tracers in the evaluation of the response to new therapies is also provided.

Original languageEnglish
Article number373
Pages (from-to)1-22
Number of pages22
JournalMedicina (Lithuania)
Issue number8
Publication statusPublished - Aug 2020


  • Immunotherapy
  • Positron emission tomography
  • Response assessment, PERCIST criteria
  • Target therapy

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Positron emission tomography-based response to target and immunotherapies in oncology'. Together they form a unique fingerprint.

Cite this